Search Results - Yu. A. Yuricheva

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness

    Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness by N. Yu. Mironov, V. V. Vlodzyanovskiy, Yu. A. Yuricheva, S. F. Sokolov, S. P. Golitsyn, L. V. Rosenstraukh, E. I. Chazov

    Published 2018-11-01

    Aim. We aimed to compare effectiveness of new  class III antiarrhythmic drug  Refralon with direct current  cardioversion (DCC) in patients with persistent atrial fibrillation (AF).Material and methods. 60  patients with persistent AF were  randomized to groups  of DCC (n=30) and  pharmacologic conv...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety

    Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety by N. Yu. Mironov, V. V. Vlodzyanovskiy, Yu. A. Yuricheva, S. F. Sokolov, S. P. Golitsyn, L. V. Rosenstraukh, E. I. Chazov

    Published 2019-01-01

    Aim. To compare safety of new class III antiarrhythmic drug Refralon with direct current cardioversion (DCC) in patients with persistent atrial fibrillation (AF). Material and methods. 60 patients with persistent AF were randomized to groups of DCC (n=30) and pharmacologic conversion (PCV; n=30). Th...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    Cavutilide (Refralon) for pharmacological cardioversion of early recurrence atrial fibrillation and flutter in blanking period after pulmonary veins isolation

    Cavutilide (Refralon) for pharmacological cardioversion of early recurrence atrial fibrillation and flutter in blanking period after pulmonary veins isolation by M. A. Zelberg, N. Yu. Mironov, Kh. M. Dzaurova, Yu. A. Yuricheva, E. B. Maykov, P. S. Novikov, D. A. Gagloeva, M. A. Krimukova, S. F. Sokolov, S. P. Golitsyn

    Published 2024-05-01

    Objective. Evaluate efficacy and safety of cavutilide (Refralon) for pharmacological cardioversion in patients with recurrent atrial fibrillation and flutter (AF/AFL), in 90days blanking period of catheter ablation.Materials and methods. included 56 patients: 46 patients with recurrent paroxysmal AF...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion

    Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion by Kh. M. Dzaurova, N. Yu. Mironov, Yu. A. Yuricheva, M. M. Belyaeva, S. F. Sokolov, N. A. Mironova, S. P. Golitsyn, O. Yu. Korennova, I. M. Zueva, E. A. Turusheva, D. S. Terekhov

    Published 2025-06-01

    Aim. To evaluate the effectiveness and safety of cavutilide in patients with a history of unsuccessful cardioversion to terminate current persistent and paroxysmal atrial fibrillation (AF) episode.Material and methods. The retrospective study included 55 patients (mean age 60±8 years; male/female ra...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter

    Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation... by D. A. Gagloeva, Kh. M. Dzaurova, M. A. Zelberg, N. Yu. Mironov, Yu. A. Yuricheva, S. F. Sokolov, M. A. Krymukova, A. I. Salpagarova, L. O. Dulaev, D. V. Pevzner, S. P. Golitsyn

    Published 2023-05-01

    Aim. To compare the efficacy and safety of chemical cardioversion (CCV) with refralon and amiodarone in patients with paroxysmal atrial fibril­lation and flutter (AF/AFL).Material and methods. Fifty five patients (mean age, 65±11 years) with paroxysmal AF/AFL were included. All patients underwent a...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  6. 6
    Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness

    Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectivene... by N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. S. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin

    Published 2021-05-01

    Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research center in cardiology) with data of other hospitals.Mat...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety

    Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety by N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. V. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin

    Published 2021-11-01

    Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research center in cardiology) with data of other hospitals.Mat...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  8. 8
    Out-patient monitoring of patients with coronary artery disease (CAD)

    Out-patient monitoring of patients with coronary artery disease (CAD) by F. T. Ageev, R. S. Akchurin, V. V. Buza, E. E. Vlasova, S. P. Golitsyn, Yu. Ye. Efremova, Yu. A. Karpov, V. V. Kukharchuk, T. A. Malkina, T. V. Martynyuk, N. A. Mironova, S. N. Nakonechnikov, E. V. Oshchepkova, M. Ya. Ruda, E. V. Sorokin, A. A. Skvortsov, S. N. Tereshchenko, I. Ye. Chazova, L. N. Chihireva, N. M. Chikhladze, G. H. Sharipova, Yu. A. Yuricheva

    Published 2015-03-01

    .

    Get full text
    Article

    Save to List
    Saved in:
  9. 9
    Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022)

    Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022) by I. E. Chazova, Yu. V. Zhernakova, N. V. Blinova, T. N. Markova, N. V. Mazurina, I. V. Zhirov, T. M. Uskach, A. A. Safiullina, O. Iu. Mironova, E. M. Elfimova, A. Yu. Litvin, E. A. Zheleznova, Yu. A. Yuricheva, V. A. Azizov, E. A. Grigorenko, Z. Ya. Rahimov, S. D. Kasymova, I. I. Mustafaev, A. R. Narzullaeva, A. G. Polupanov, A. Sh. Sarybaev, N. Z. Srozhidinova

    Published 2022-10-01

    Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambigui...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  10. 10
    EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021)

    EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021) by I. E. Chazova, M. V. Shestakova, Yu. V. Zhernakova, N. V. Blinova, T. N. Markova, N. V. Mazurina, M. V. Ezhov, S. N. Tereshchenko, I. V. Zhirov, A. L. Komarov, O. Yu. Mironova, Yu. A. Yuricheva, O. Yu. Suhareva, O. A. Kislyak, A. M. Mkrtumyan, V. I. Podzolkov, V. A. Azizov, P. A. Zelveyan, E. A. Grigorenko, Z. Ya. Rahimov, A. Sh. Sarybaev, S. D. Kasymova, A. R. Narzullaeva

    Published 2021-05-01

    The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between t...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: